Stay updated on SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page’s footer revision label changed from v3.7.2 to v3.8.0.
    Difference
    0.1%
    Check dated 2026-10-30T11:07:27.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    A banner announces that NIH is transitioning terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    0.8%
    Check dated 2026-10-23T11:23:52.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The site footer revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-16T11:19:05.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision label changed from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-09T12:15:07.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    A new revision entry, v3.7.0, was added to the study history. The previous revision v3.6.6 was removed from the visible history.
    Difference
    0.1%
    Check dated 2026-09-18T12:34:35.000Z thumbnail image
  6. Check
    65 days ago
    Change Detected
    Summary
    A new revision entry 'Revision: v3.6.6' is added to the record history, representing the latest update to the study record's documentation. This updates the history log to reflect the most recent version.
    Difference
    0.1%
    Check dated 2026-08-28T11:47:40.000Z thumbnail image

Stay in the know with updates to SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page.